Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | How will the treatment landscape for uveal melanoma change in the future?

Sapna Patel • 23 Oct 2026
ESMO 2026
General Melphalan Tebentafusp

Sapna Patel, MD, Colorado Cancer Center, Aurora, CO, highlights the potential for a paradigm shift in the treatment of metastatic uveal melanoma, with emerging data on targeted therapies, such as tebentafusp and melphalan via percutaneous hepatic perfusion, offering new possibilities for tumor control. While these advancements may not lead to cures or long-term control, they will allow for exploration of sequencing and combination strategies, similar to those used in skin melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sapna Patel

The clinical significance of the INTerpath-001 and STARBOARD in melanoma
0:53
The clinical significance of the INTerpath-001 and STARBOARD in melanoma
Sapna Patel • 23 Oct 2026
Skin cancer highlights at ESMO 2026: INTerpath-001 and STARBOARD
2:12
Skin cancer highlights at ESMO 2026: INTerpath-001 and STARBOARD
Sapna Patel • 23 Oct 2026
Challenges and opportunities in personalized cancer vaccines
2:18
Challenges and opportunities in personalized cancer vaccines
Sapna Patel • 23 Oct 2026
Phase Ia/b trial of IMA203, a PRAME-directed TCR therapy, in uveal melanoma
2:44
Phase Ia/b trial of IMA203, a PRAME-directed TCR therapy, in uveal melanoma
Sapna Patel • 17 Oct 2025

Related Videos

Evaluating immunotherapy benefit beyond survival: toxicity and quality of life
1:43
Evaluating immunotherapy benefit beyond survival: toxicity and quality of life
Abhenil Mittal • 24 Oct 2026
Survival maturity of perioperative and adjuvant checkpoint inhibitor approvals
1:41
Survival maturity of perioperative and adjuvant checkpoint inhibitor approvals
Abhenil Mittal • 24 Oct 2026
Challenges and opportunities in personalized cancer vaccines
2:18
Challenges and opportunities in personalized cancer vaccines
Sapna Patel • 23 Oct 2026
Oral pan-RAS inhibitor GFH276 in previously treated RAS-mutated solid tumors
1:37
Oral pan-RAS inhibitor GFH276 in previously treated RAS-mutated solid tumors
Yuxiang Ma • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals